The Working Group for Idiopathic Intestinal Inflammation of the Czech Republic has drawn up draft recommendations regarding the initiation of biological therapy (infliximab and adalimumab) in Crohn's disease and ulcerative colitis, treatment of extraintestinal manifestations, contraindications to biological treatment, biological treatment in special situations, and monitoring the effectiveness and safety of biological treatment.